AR112284A1 - Combinación que comprende palbociclib y ácido 6-(2,4-diclorofenil)-5-[4-[(3s)-1-(3-fluoropropil)pirrolidin-3-il]oxifenil]-8,9-dihidro-7h-benzo[7]anuleno-2-carboxílico - Google Patents
Combinación que comprende palbociclib y ácido 6-(2,4-diclorofenil)-5-[4-[(3s)-1-(3-fluoropropil)pirrolidin-3-il]oxifenil]-8,9-dihidro-7h-benzo[7]anuleno-2-carboxílicoInfo
- Publication number
- AR112284A1 AR112284A1 ARP180102058A AR112284A1 AR 112284 A1 AR112284 A1 AR 112284A1 AR P180102058 A ARP180102058 A AR P180102058A AR 112284 A1 AR112284 A1 AR 112284A1
- Authority
- AR
- Argentina
- Prior art keywords
- acid
- annulene
- fluoropropyl
- pyrrolidin
- benzo
- Prior art date
Links
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/40—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with one nitrogen as the only ring hetero atom, e.g. sulpiride, succinimide, tolmetin, buflomedil
- A61K31/4015—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with one nitrogen as the only ring hetero atom, e.g. sulpiride, succinimide, tolmetin, buflomedil having oxo groups directly attached to the heterocyclic ring, e.g. piracetam, ethosuximide
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/40—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with one nitrogen as the only ring hetero atom, e.g. sulpiride, succinimide, tolmetin, buflomedil
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
- A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
- A61K31/519—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim ortho- or peri-condensed with heterocyclic rings
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K2300/00—Mixtures or combinations of active ingredients, wherein at least one active ingredient is fully defined in groups A61K31/00 - A61K41/00
Abstract
Se proporcionan en la presente memoria una combinación de palbociclib y del ácido 6-(2,4-diclorofenil)-5-[4-[(3S)-1-(3-fluoropropil)pirrolidin-3-il]oxifenil]-8,9-dihidro-7H-benzo[7]anuleno-2-carboxílico o una de sus sales farmacéuticamente aceptables, una composición farmacéutica que contiene dicha combinación, y sus usos terapéuticos, en particular para el tratamiento del cáncer, incluyendo el cáncer de mama. Reivindicación 5: Una composición farmacéutica que comprende ácido 6-(2,4-diclorofenil)-5-[4-[(3S)-1-(3-fluoropropil)pirrolidin-3-il]oxifenil]-8,9-dihidro-7H-benzo[7]anuleno-2-carboxílico, o una de sus sales farmacéuticamente aceptables, y palbociclib, y al menos un excipiente farmacéuticamente aceptable. Reivindicación 9: Compuesto ácido 6-(2,4-diclorofenil)-5-[4-[(3S)-1-(3-fluoropropil)pirrolidin-3-il]oxifenil]-8,9-dihidro-7H-benzo[7]anuleno-2-carboxílico o una de sus sales farmacéuticamente aceptables para usar en el tratamiento de cáncer por coadministración con palbociclib.
Applications Claiming Priority (2)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
US201762536121P | 2017-07-24 | 2017-07-24 | |
EP17305998.1A EP3434272A1 (en) | 2017-07-25 | 2017-07-25 | Combination comprising palbociclib and 6-(2,4-dichlorophenyl)-5-[4-[(3s)-1-(3-fluoropropyl)pyrrolidin-3-yl]oxyphenyl]-8,9-dihydro-7h-benzo[7]annulene-2-carboxylic acid |
Publications (1)
Publication Number | Publication Date |
---|---|
AR112284A1 true AR112284A1 (es) | 2019-10-09 |
Family
ID=59569252
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
ARP180102058 AR112284A1 (es) | 2017-07-24 | 2018-07-24 | Combinación que comprende palbociclib y ácido 6-(2,4-diclorofenil)-5-[4-[(3s)-1-(3-fluoropropil)pirrolidin-3-il]oxifenil]-8,9-dihidro-7h-benzo[7]anuleno-2-carboxílico |
Country Status (29)
Country | Link |
---|---|
US (2) | US11260057B2 (es) |
EP (2) | EP3434272A1 (es) |
JP (1) | JP6741897B1 (es) |
KR (1) | KR20200031622A (es) |
CN (1) | CN111107851B (es) |
AR (1) | AR112284A1 (es) |
AU (1) | AU2018308871A1 (es) |
BR (1) | BR112020001398A2 (es) |
CA (1) | CA3070754A1 (es) |
CO (1) | CO2020000240A2 (es) |
DK (1) | DK3658147T3 (es) |
ES (1) | ES2906279T3 (es) |
HR (1) | HRP20212030T1 (es) |
HU (1) | HUE057271T2 (es) |
IL (1) | IL272166B2 (es) |
LT (1) | LT3658147T (es) |
MA (1) | MA49673B1 (es) |
MY (1) | MY195271A (es) |
PH (1) | PH12020500091A1 (es) |
PL (1) | PL3658147T3 (es) |
PT (1) | PT3658147T (es) |
RS (1) | RS62837B1 (es) |
RU (1) | RU2764116C2 (es) |
SG (1) | SG11202000367RA (es) |
SI (1) | SI3658147T1 (es) |
TW (1) | TWI768087B (es) |
UY (1) | UY37818A (es) |
WO (1) | WO2019020559A1 (es) |
ZA (1) | ZA202000145B (es) |
Families Citing this family (9)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
EP3434272A1 (en) * | 2017-07-25 | 2019-01-30 | Sanofi | Combination comprising palbociclib and 6-(2,4-dichlorophenyl)-5-[4-[(3s)-1-(3-fluoropropyl)pyrrolidin-3-yl]oxyphenyl]-8,9-dihydro-7h-benzo[7]annulene-2-carboxylic acid |
HUE059362T2 (hu) | 2018-09-07 | 2022-11-28 | Sanofi Sa | Metil-6-(2,4-diklórfenil)-5-[4-[(3S)-1-(3-fluorpropil)pirrolidin-3-il]oxifenil]-8,9 -dihidro-7H-benzo[7]annulén-2-karboxilát sói és azok elõállítási eljárásai |
MX2021013711A (es) * | 2019-05-09 | 2021-12-10 | Sanofi Sa | Acido 6-(2,4-diclorofenil)-5-[4-[(3s)-1-(3-fluoropropil)pirrolidin -3-il]oxifenil]-8,9-dihidro-7h-benzo[7]anuleno-2-carboxilico para su uso en pacientes con cancer de mama metastasico o avanzado. |
JP2023504912A (ja) * | 2019-12-09 | 2023-02-07 | サノフイ | 7h-ベンゾ[7]アヌレン-2-カルボン酸誘導体の結晶形態 |
TW202146007A (zh) * | 2020-02-27 | 2021-12-16 | 法商賽諾菲公司 | 包含阿培利司(alpelisib)與6-(2,4-二氯苯基)-5-[4-[(3s)-1-(3-氟丙基)吡咯啶-3-基]氧苯基]-8,9-二氫-7h-苯并[7]輪烯-2-羧酸之組合 |
CA3199466A1 (en) * | 2020-11-23 | 2022-05-27 | Monsif Bouaboula | Combination comprising abemaciclib and 6-(2,4-dichlorophenyl)-5-[4-[(3s)-1-(3-fluoropropyl)pyrrolidin-3-yl]oxyphenyl]-8,9-dihydro-7h-benzo[7]annulene-2-carboxylic acid |
TW202302084A (zh) * | 2021-03-02 | 2023-01-16 | 法商賽諾菲公司 | 以安森司坦和帕博西尼治療乳癌 |
TW202304425A (zh) * | 2021-04-12 | 2023-02-01 | 法商賽諾菲公司 | 包含瑞博西尼和安森司群(amcenestrant)的組合 |
KR20230130261A (ko) | 2022-03-03 | 2023-09-12 | 인하대학교 산학협력단 | 암의 예방 또는 치료용 조성물 |
Family Cites Families (29)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
JPH06506467A (ja) | 1991-03-08 | 1994-07-21 | ローヌ−プーラン ローラー インターナショナル(ホウルディングス) インコーポレイテッド | 多環式三級アミンポリ芳香族スクアレンシンセターゼインヒビター |
DE19833786A1 (de) | 1998-07-18 | 2000-01-20 | Schering Ag | Benzocycloheptene, Verfahren zu ihrer Herstellung, pharmazeutische Präparate, die diese enthalten, sowie deren Verwendung zur Herstellung von Arzneimitteln |
ATE286893T1 (de) | 2001-01-24 | 2005-01-15 | Chiesi Farma Spa | 2h-1-benzopyran-derivative, prozesse zu ihrer herstellung und pharmazeutische zusammensetzungen |
EE200400061A (et) | 2001-08-11 | 2004-04-15 | Bristol-Myers Squibb Pharma Company | Trifenüületüleeni derivaadid kui selektiivsed östrogeeniretseptori modulaatorid ja neid sisaldavad ravimkoostised |
SI1501819T1 (sl) | 2002-04-24 | 2011-01-31 | Merck Sharp & Dohme | Modulatorji estrogen receptorjev |
CA2512000C (en) | 2002-12-26 | 2011-08-09 | Eisai Co., Ltd. | Selective estrogen receptor modulator |
AU2005267385B2 (en) | 2004-06-25 | 2011-11-10 | Janssen Pharmaceutica N.V. | Quaternary salt CCR2 antagonists |
EP1896391B1 (en) | 2005-06-14 | 2015-08-12 | Baylor University | Combretastatin analogs with tubulin binding activity |
US8127618B1 (en) | 2007-05-18 | 2012-03-06 | Pacesetter, Inc. | Implantable micro-electromechanical system sensor |
EP2048126A1 (de) | 2007-10-11 | 2009-04-15 | Bayer Schering Pharma AG | Benzocycloheptanderivate als selektiv wirksame Estrogene |
DE102010030538A1 (de) | 2010-06-25 | 2011-12-29 | Bayer Schering Pharma Aktiengesellschaft | 6,7-Dihydro-5H-benzo[7]annulen-Derivate, Verfahren zu ihrer Herstellung, pharmazeutische Präparate die diese enthalten, sowie deren Verwendung zur Herstellung von Arzneimitteln |
GB2483736B (en) | 2010-09-16 | 2012-08-29 | Aragon Pharmaceuticals Inc | Estrogen receptor modulators and uses thereof |
ES2586908T3 (es) | 2010-12-24 | 2016-10-19 | Merck Sharp & Dohme B.V. | Derivados de azetidina N-sustituidos |
DE102011087987A1 (de) | 2011-12-08 | 2013-06-13 | Bayer Intellectual Property Gmbh | 6,7-Dihydro-5H-benzo[7]annulen-Derivate, Verfahren zu ihrer Herstellung, pharmazeutische Präparate die diese enthalten, sowie deren Verwendung zur Herstellung von Arzneimitteln |
JP2015504049A (ja) | 2011-12-30 | 2015-02-05 | センタウルス・バイオファーマ・カンパニー・リミテッドCentaurus Biopharma Co.,Ltd. | 新規アリールアルケン誘導体およびその選択的エストロゲン受容体調整剤における使用 |
CN102584687A (zh) | 2011-12-30 | 2012-07-18 | 北京赛林泰医药技术有限公司 | 作为选择性雌激素受体调节剂的乙烯衍生物 |
LT3033086T (lt) * | 2013-08-14 | 2021-12-27 | Novartis Ag | Kombinuota terapija vėžiui gydyti |
WO2015028409A1 (de) | 2013-08-27 | 2015-03-05 | Bayer Pharma Aktiengesellschaft | 6,7-dihydro-5h-benzo[7]annulen-derivate, verfahren zu ihrer herstellung, pharmazeutische präparate die diese enthalten, sowie deren verwendung zur herstellung von arzneimitteln |
RS60824B1 (sr) | 2014-12-18 | 2020-10-30 | Hoffmann La Roche | Tetrahidro-pirido[3,4-b]indoli kao modulatori estrogenih receptora i njihova upotreba |
US9845291B2 (en) | 2014-12-18 | 2017-12-19 | Genentech, Inc. | Estrogen receptor modulators and uses thereof |
WO2016146591A1 (en) * | 2015-03-16 | 2016-09-22 | Astrazeneca Ab | Combination treatment |
AR104068A1 (es) * | 2015-03-26 | 2017-06-21 | Hoffmann La Roche | Combinaciones de un compuesto inhibidor de fosfoinosítido 3-cinasa y un compuesto inhibidor de cdk4/6 para el tratamiento del cáncer |
CN113288887A (zh) * | 2015-04-29 | 2021-08-24 | 雷迪厄斯制药公司 | 用于治疗癌症的方法 |
CN106924210A (zh) * | 2015-12-29 | 2017-07-07 | 北京新领先医药科技发展有限公司 | 一种含有帕布昔利布的胶囊剂及其制备方法 |
HUE057892T2 (hu) | 2016-02-15 | 2022-06-28 | Sanofi Sa | Eljárások és közitermékek új, helyettesített 6,7-dihidro-5H-benzo[7]annulén-származékok elõállítására |
AU2017362460B2 (en) | 2016-11-17 | 2021-07-22 | Sanofi | Novel substituted N-(3-fluoropropyl)-pyrrolidine compounds, processes for their preparation and therapeutic uses thereof |
EP3434272A1 (en) * | 2017-07-25 | 2019-01-30 | Sanofi | Combination comprising palbociclib and 6-(2,4-dichlorophenyl)-5-[4-[(3s)-1-(3-fluoropropyl)pyrrolidin-3-yl]oxyphenyl]-8,9-dihydro-7h-benzo[7]annulene-2-carboxylic acid |
HUE059362T2 (hu) | 2018-09-07 | 2022-11-28 | Sanofi Sa | Metil-6-(2,4-diklórfenil)-5-[4-[(3S)-1-(3-fluorpropil)pirrolidin-3-il]oxifenil]-8,9 -dihidro-7H-benzo[7]annulén-2-karboxilát sói és azok elõállítási eljárásai |
CA3119742A1 (en) * | 2018-11-16 | 2020-05-22 | Arqule, Inc. | Pharmaceutical combination for treatment of cancer |
-
2017
- 2017-07-25 EP EP17305998.1A patent/EP3434272A1/en not_active Ceased
-
2018
- 2018-07-23 MA MA49673A patent/MA49673B1/fr unknown
- 2018-07-23 MY MYPI2020000179A patent/MY195271A/en unknown
- 2018-07-23 DK DK18740615.2T patent/DK3658147T3/da active
- 2018-07-23 WO PCT/EP2018/069901 patent/WO2019020559A1/en unknown
- 2018-07-23 HU HUE18740615A patent/HUE057271T2/hu unknown
- 2018-07-23 HR HRP20212030TT patent/HRP20212030T1/hr unknown
- 2018-07-23 RS RS20220068A patent/RS62837B1/sr unknown
- 2018-07-23 PT PT187406152T patent/PT3658147T/pt unknown
- 2018-07-23 ES ES18740615T patent/ES2906279T3/es active Active
- 2018-07-23 KR KR1020207002003A patent/KR20200031622A/ko not_active Application Discontinuation
- 2018-07-23 LT LTEPPCT/EP2018/069901T patent/LT3658147T/lt unknown
- 2018-07-23 JP JP2020503737A patent/JP6741897B1/ja active Active
- 2018-07-23 AU AU2018308871A patent/AU2018308871A1/en active Pending
- 2018-07-23 CA CA3070754A patent/CA3070754A1/en active Pending
- 2018-07-23 EP EP18740615.2A patent/EP3658147B1/en active Active
- 2018-07-23 RU RU2020107416A patent/RU2764116C2/ru active
- 2018-07-23 BR BR112020001398-6A patent/BR112020001398A2/pt active Search and Examination
- 2018-07-23 CN CN201880048755.5A patent/CN111107851B/zh active Active
- 2018-07-23 US US16/634,089 patent/US11260057B2/en active Active
- 2018-07-23 IL IL272166A patent/IL272166B2/en unknown
- 2018-07-23 SG SG11202000367RA patent/SG11202000367RA/en unknown
- 2018-07-23 PL PL18740615T patent/PL3658147T3/pl unknown
- 2018-07-23 SI SI201830528T patent/SI3658147T1/sl unknown
- 2018-07-24 AR ARP180102058 patent/AR112284A1/es unknown
- 2018-07-24 UY UY0001037818A patent/UY37818A/es not_active Application Discontinuation
- 2018-07-24 TW TW107125442A patent/TWI768087B/zh active
-
2020
- 2020-01-09 ZA ZA2020/00145A patent/ZA202000145B/en unknown
- 2020-01-10 PH PH12020500091A patent/PH12020500091A1/en unknown
- 2020-01-13 CO CONC2020/0000240A patent/CO2020000240A2/es unknown
-
2022
- 2022-01-19 US US17/579,187 patent/US20220362248A1/en active Pending
Also Published As
Similar Documents
Publication | Publication Date | Title |
---|---|---|
AR112284A1 (es) | Combinación que comprende palbociclib y ácido 6-(2,4-diclorofenil)-5-[4-[(3s)-1-(3-fluoropropil)pirrolidin-3-il]oxifenil]-8,9-dihidro-7h-benzo[7]anuleno-2-carboxílico | |
CO2019007810A2 (es) | Compuestos de amino-triazolopiridina y su uso en el tratamiento del cáncer | |
CO2019015090A2 (es) | Métodos de tratamiento para la fibrosis cística | |
CU20160109A7 (es) | Compuestos de indazol como inhibidores de irak4 | |
NI201700101A (es) | Composiciones farmacéuticas que comprenden n - (3, 5 - dimetoxifenil) - n'- (1-metiletil) - n - [3-(1-metil-1h-pirazol-4-il) quinoxalina-6-il]etano-1,2-diamina | |
CY1120088T1 (el) | Παραγωγα τυπου αζαϊνδαζολιου ή διαζαϊνδαζολιου ως φαρμακo | |
CL2017000469A1 (es) | Derivados de tetrahidronaftaleno que inhiben la proteina mcl-1 | |
CO2018002060A2 (es) | Compuestos farmacéuticos | |
CL2019000056A1 (es) | Sales y formas cristalinas del ácido 2-(3r,5r,6s)-5-(3-clorofenil)-6-(4-clorofenil)-1-(s)-1(isopropilsufonil)-3-metilbutan-2-il)-3-metil-2-oxopiperidin-3-il)acético; proceso de preparación de una de las sales; composición farmacéutica que comprende; útiles para tratar cáncer. (solicitud divisional 201503589) | |
CR20150628A (es) | Derivados de la pirazolopirrolidina y su uso en el tratamiento de enfermedades | |
AR059948A1 (es) | Formas farmaceuticas y metodos de tratamiento que usan un inhibidor de la tirosinacinasa | |
CO2018004857A2 (es) | Derivados de dihidroimidazopirazinona usados en el tratamiento del cáncer | |
CL2015002608A1 (es) | Compuesto de amino-pirazol y usos medicinales relacionados. | |
UY34974A (es) | Piridazina 1,4 disustituida, análogos de la misma y métodos para tratar las enfermedades relacionadas con deficiencia del smn | |
GT200600096A (es) | Composicion farmaceutica para el tratamiento del cancer | |
AR103680A1 (es) | Inhibidores selectivos de bace1 | |
UY30267A1 (es) | Nuevos derivados de la tioxantina , composiciones farmacéuticas que los contienen, procedimientos de preparacion y aplicaciones | |
CO6491060A2 (es) | Compuestos y composiciones para el tratamiento de enfermedades parasitarias | |
AR096892A1 (es) | Una combinación farmacéutica para el tratamiento del melanoma | |
CL2018001830A1 (es) | Formulaciones de 2-(4-clorofenil)-n-((2-(2,6-dioxopiperidin-3-il)-1-oxoisoindolin-5-il)metil)-2,2-difluoroacetamida | |
DOP2016000254A (es) | Formulaciones farmeceuticas de inhibidor de la quinasa pan-raf, procedimientos para su preparacion, y metodos de uso. | |
BR112019007576A2 (pt) | compostos de bifenil sulfonamida para o tratamento de doenças ou transtornos renais | |
AR104068A1 (es) | Combinaciones de un compuesto inhibidor de fosfoinosítido 3-cinasa y un compuesto inhibidor de cdk4/6 para el tratamiento del cáncer | |
AR094707A1 (es) | Compuesto de quinazolin-4-amina, composición farmacéutica que lo comprende y su uso para el tratamiento de una enfermedad mediada por la quinasa rip2 | |
CO2019004004A2 (es) | Composición farmacéutica y método para el tratamiento de la enfermedad del hígado graso no alcohólico |